article thumbnail

'Appropriate' transition period for COVID-19 test EUAs when public health emergency ends

Healthcare Dive

The FDA is planning to give holders of EUAs for COVID-19 diagnostics and other devices 180 days notice of its intent to end their authorizations, in anticipation of U.S. public health emergency declarations stopping.

COVID-19 307
article thumbnail

Litigation Challenges Prioritization of Race or Ethnicity in Allocating COVID-19 Therapies

Bill of Health

Food & Drug Administration (FDA) encouraged several states to adopt policies that prioritized race or ethnicity in the allocation of monoclonal antibody treatments and oral antivirals for the treatment of SARS-CoV-2. By James Lytle. Recent guidance from the U.S. Emphasis in original.)

COVID-19 246
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Selects Aetion Evidence Platform to Assess In-Patient COVID-19 Treatments

HIT Consultant

Food and Drug Administration (FDA) has contracted with them to use their Aetion Evidence Platform® to rapidly assess in-patient COVID-19 treatments and advance regulatory science to help determine when, where and how to use RWD. Enables rapid evidence generation for COVID-19 and future pandemics.

article thumbnail

FDA takes N95 respirators off medical device shortage list

Healthcare Dive

Respirators were one of the first medical devices identified as being in critical shortage during the COVID-19 public health emergency, the agency said.

COVID-19 261
article thumbnail

First OTC, app-connected COVID-19 test authorized by FDA

Mobi Health News

Alongside step-by-step instructions, the Ellume COVID-19 Home Test's accompanying app automatically reports users' results to the relevant public health authorities.

COVID-19 124
article thumbnail

Accessing COVID-19 mRNA Vaccines for Research: The Re-emergence of the Tragedy of the ‘Anticommons’

Bill of Health

Some COVID-19 vaccine manufacturers in the US have refused to share vaccine samples for research purposes , creating an access issue with the potential to delay comparator studies, follow-on research, and new vaccine / drug development. However, the act of submitting an application to the FDA based on such research (e.g.,

COVID-19 167
article thumbnail

Reflections on Procedural Barriers to Pediatric COVID Vaccine Access

Bill of Health

When news broke last week that Pfizer-BioNTech was submitting for Emergency Use Authorization (EUA) a two-dose COVID vaccine regimen for children under 5 to the U.S. Food and Drug Administration (FDA), many parents felt a glimmer of hope after a long time. million children have tested positive for COVID since the pandemic, over 3.5

COVID-19 343